Management of endometrial cancer: issues and controversies

Although endometrial cancer (EC) is the most common gynecologic cancer in developed countries, several aspects of its management are still controversial. In particular, the need to perform lymphadenectomy represents an important matter of discussion. Because of the discordant results in the literature, it is still not possible to draft any definitive conclusions regarding the therapeutic value of lymph node dissection. The present review discusses the role of lymphadenectomy in the setting of EC, risk factors for lymphatic spread, identification of patients at risk for lymph node dissemination, and the current evidence for adjuvant therapies in patients with positive nodes. Reasons for the difficulty in demonstrating any therapeutic value of pelvic and para-aortic lymphadenectomy are also discussed.

Adjuvant therapy; Endometrial cancer; Lymphadenectomy; Staging; Survival.

[1] Siegel R., Ma J., Zou Z., Jemal A.: “Cancer statistics: 2014”. CA Cancer J. Clin., 2014, 64, 9. Epub 2014 Jan 7.

[2] Bogani G., Dowdy S.C., Cliby W.A., Ghezzi F., Rossetti D., Mariani A.: “Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence”. J. Obstet. Gynaecol. Res., 2014, 40, 301.

[3] Todo Y., Sakuragi N.: “Systematic lymphadenectomy in endometrial cancer”. J. Obstet. Gynaecol. Res., 2013, 39, 471. Epub 2012 Dec 21.

[4] Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Gra-ham J.E., Heller P.B.: “Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study”. Cancer, 1987, 60, 2035.

[5] Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., et al.: “Carcinoma of the corpus uteri: FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, S105.

[6] Benedetti Panici P., Basile S., Maneschi F., Alberto Lissoni A., Signorelli M., Scambia G., et al.: “Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial”. J. Natl. Cancer Inst., 2008, 100, 1707. Epub 2008 Nov 25.

[7] Kitchener H., Swart A.M., Qian Q., Amos C., Parmar M.K., ASTEC Study Group: “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study”. Lancet, 2009, 373, 125. Epub 2008 Dec 16. Erratum in: Lancet, 2009, 373, 1764.

[8] May K., Bryant A., Dickinson H.O., Kehoe S., Morrison J.: “Lymphadenectomy for the management of endometrial cancer”. Cochrane Database Syst. Rev., 2010, 1, CD007585.

[9] Mariani A., Dowdy S.C., Cliby W.A., Gostout B.S., Jones M.B., Wilson T.O., et al.: “Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging”. Gynecol. Oncol., 2008, 109, 11. Epub 2008 Mar 4.

[10] Todo Y., Kato H., Kaneuchi M., Watari H., Takeda M., Sakuragi N.: “Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis”. Lancet, 2010 375, 1165. Epub 2010 Feb 24. Erratum in: Lancet, 2010, 376, 594.

[11] Kumar S., Mariani A., Bakkum-Gamez J.N., Weaver A.L., McGree M. E., Keeney G.L., et al.: “Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer”. Gynecol. Oncol., 2013, 130, 441. Epub 2013 Jun 5.

[12] Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Calori G., Podratz K.C.: “Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?” Am. J. Obstet. Gynecol., 2000, 182, 1506.

[13] Dowdy S.C., Borah B.J., Bakkum-Gamez J.N., Weaver A.L., Mc- Gree M.E., Haas L.R., et al.: “Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer”. Gynecol. Oncol., 2012, 127, 5. Epub 2012 Jul 3.

[14] Kumar S., Podratz K.C., Bakkum-Gamez J.N., Dowdy S.C., Weaver A.L., McGree M.E., et al.: “Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer”. Gynecol. Oncol., 2014, 132, 38. Epub 2013 Oct 9.

[15] Kumar S., Medeiros F., Dowdy S.C., Keeney G.L., Bakkum-Gamez J.N., Podratz K.C., et al.: “A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer”. Gynecol. Oncol., 2012, 127, 525. Epub 2012 Aug 29.

[16] Morotti M., Menada M.V., Moioli M., Sala P., Maffeo I., Abete L., et al.: “Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia”. Gynecol. Oncol., 2012, 125, 536. Epub 2012 Feb 21.

[17] Papadia A., Azioni G., Brusaca B., Fulcheri E., Nishida K., Menoni S., et al.: “Frozen section underestimates the need for surgical staging in endometrial cancer patients”. Int. J. Gynecol. Cancer, 2009, 19, 1570.

[18] AlHilli M.M., Podratz K.C., Dowdy S.C., Bakkum-Gamez J.N., Weaver A.L., McGree M.E., et al.: “Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer”. Gynecol. Oncol., 2013, 128, 294. Epub 2012 Oct

17.

[19] Todo Y., Okamoto K., Hayashi M., Minobe S., Nomura E., Hareyama H., et al.: “A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy”. Gynecol. Oncol., 2007, 104, 623. Epub 2006 Nov 13.

[20] Todo Y., Sakuragi N., Nishida R., Yamada T., Ebina Y., Yamamoto R., et al.: “Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma”. Am. J. Obstet. Gynecol., 2003, 188, 1265. Erratum in: Am. J. Obstet. Gynecol., 2003, 189, 567.

[21] AlHilli M.M., Podratz K.C., Dowdy S.C., Bakkum-Gamez J.N., Weaver A.L., McGree M.E., et al.: “Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer”. Gynecol. Oncol., 2013, 131, 103. Epub 2013 Jul 9.

[22] Crivellaro C., Signorelli M., Guerra L., De Ponti E., Pirovano C., Fruscio R., et al.: “Tailoring systematic lymphadenectomy in highrisk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT”. Gynecol. Oncol., 2013, 130, 306. Epub 2013 May 23.

[23] Kalogera E., Scholler N., Powless C., Weaver A., Drapkin R., Li J., et al.: “Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer”. Gynecol. Oncol., 2012, 124, 270. Epub 2011 Oct 28.

[24] Todo Y., Watari H., Okamoto K., Hareyama H., Minobe S., Kato H., et al.: “Tumor volume successively reflects the state of disease progression in endometrial cancer”. Gynecol. Oncol., 2013, 129, 472. Epub 2013 Mar 5.

[25] American College of Obstetricians and Gynecologists: “ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer”. Obstet. Gynecol., 2005, 106, 413.

[26] Mariani A., Dowdy S.C., Cliby W.A., Haddock M.G., Keeney G.L., Lesnick T.G., et al.: “Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients”. Gynecol. Oncol., 2006, 101, 200. Epub 2006 Feb 28.

[27] Todo Y., Suzuki Y., Azuma M., Hatanaka Y., Konno Y., Watari H., et al.: “Ultrastaging of para-aortic lymph nodes in stage IIIC1 endometrial cancer: a preliminary report”. Gynecol. Oncol., 2012, 127, 532. Epub 2012 Aug 30.

[28] Larson D.M., Johnson K., Olson K.A.: “Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: morbidity and mortality”. Obstet. Gynecol., 1992, 79, 998.

[29] Homesley H.D., Kadar N., Barrett R.J., Lentz S.S.: “Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma”. Am. J. Obstet. Gynecol., 1992, 167, 1225.

[30] Dowdy S.C., Borah B.J., Bakkum-Gamez J.N., Kumar S., Weaver A.L., McGree M.E., et al.: “Factors predictive of postoperative morbidity and cost in patients with endometrial cancer”. Obstet. Gynecol., 2012, 120, 1419.

[31] Bogani G., Cromi A., Uccella S., Serati M., Casarin J., Mariani A., et al.: ‘Laparoscopic staging in women older than 75 years with early-stage endometrial cancer: comparison with open surgical operation”. Menopause, 2014, 21, 945. doi: 10.1097/GME. 0000000000000202.

[32] Bogani G., Cromi A., Uccella S., Serati M., Casarin J., Pinelli C., et al.: “Perioperative and long-term outcomes of laparoscopic, open abdominal, and vaginal surgery for endometrial cancer in patients aged 80 years or older”. Int. J. Gynecol. Cancer, 2014, 24, 894.

[33] Dowdy SC, Aletti G, Cliby WA, Podratz KC, Mariani A. Extra-peritoneal laparoscopic para-aortic lymphadenectomy: a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol. 2008 Dec;111(3):418-24. Epub 2008 Oct 2.

[34] Bogani G., Cromi A., Uccella S., Serati M., Casarin J., Pinelli C., et al.: “Safety of perioperative aspirin therapy in minimally invasive endometrial cancer staging”. J. Minim. Invasive Gynecol., 2014, 21, 636. Epub 2014 Jan 22.

[35] Bogani G., Uccella S., Cromi A., Serati M., Casarin J., Pinelli C., et al.: “Low vs standard pneumoperitoneum pressure during laparoscopic hysterectomy: prospective randomized trial”. J. Minim. Invasive Gynecol., 2014, 21, 466. Epub 2013 Dec 25.

[36] Angioli R., Plotti F., Cafa E.V., Dugo N., Capriglione S., Terranova C., et al.: “Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 170, 539. Epub 2013 Aug 7.

[37] van de Poll-Franse L.V., Pijnenborg J.M., Boll D., Vos M.C., vanden Berg H., Lybeert M.L., et al.: “Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs no adjuvant regional treatment in early-stage endometrial carcinoma: a large population-based study”. Gynecol. Oncol., 2012, 127, 153. Epub 2012 Jun 13.

[38] Kitchener H.C.: “Sentinel-node biopsy in endometrial cancer: a winwin scenario?” Lancet Oncol., 2011, 12, 413. Epub 2011 Apr 12.

[39] Leitao M.M. Jr., Khoury-Collado F., Gardner G., Sonoda Y., Brown C.L., Alektiar K.M., et al.: “Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer”. Gynecol. Oncol., 2013, 129, 38. Epub 2013 Jan 12.

[40] Abu-Rustum N.R.: “Update on sentinel node mapping in uterine cancer: 10-year experience at Memorial Sloan-Kettering Cancer Center”. J. Obstet. Gynaecol. Res., 2014, 40, 327.

[41] McMeekin D.S., Lashbrook D., Gold M., Scribner D.R., Kamelle S., Tillmanns T.D., et al.: “Nodal distribution and its significance in FIGO stage IIIc endometrial cancer”. Gynecol. Oncol., 2001, 82, 375.

[42] Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Aletti G., Podratz K.C.: “Stage IIIC endometrioid corpus cancer includes distinct subgroups”. Gynecol. Oncol., 2002, 87, 112.

[43] Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H.D., Malfetano J.H., et al.: “Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study”. Gynecol. Oncol., 2005, 97, 755.

[44] Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al.: “Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study”. J. Clin. Oncol., 2006, 24, 36. Epub 2005 Dec 5.

[45] Klopp A.H., Jhingran A., Ramondetta L., Lu K., Gershenson D.M., Eifel P.J.: “Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation”. Gynecol. Oncol., 2009, 115, 6. Epub 2009 Jul 25.

[46] Hogberg T., Signorelli M., de Oliveira C.F., Fossati R., Lissoni A.A., Sorbe B., et al.: “Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer: results from two randomised studies”. Eur. J. Cancer, 2010, 46, 2422. Epub 2010 Jul 7.

[47] Geller M.A., Ivy J.J., Ghebre R., Downs L.S. Jr., Judson P.L., Carson L.F., et al.: “A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer”. Gynecol. Oncol., 2011, 121, 112. Epub 2011 Jan 15.

[48] Lee L.J., Viswanathan A.N.: “Combined chemotherapy and radiation improves survival for node-positive endometrial cancer”. Gynecol. Oncol., 2012, 127, 32. Epub 2012 Jun 24.

[49] Brown A.P., Gaffney D.K., Dodson M.K., Soisson A.P., Belnap T.W., Alleman K., et al.: ‘Survival analysis of endometrial cancer patients with positive lymph nodes”. Int. J. Gynecol. Cancer, 2013, 23, 861.

[50] Secord A.A., Geller M.A., Broadwater G., Holloway R., Shuler K., Dao N.Y., et al.: “A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer”. Gynecol. Oncol., 2013, 128, 65. Epub 2012 Oct 17.

[51] Ayeni T.A., Bakkum-Gamez J.N., Mariani A., McGree M.E., Weaver A.L., Haddock M.G., et al.: “Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas”. Gynecol. Oncol., 2013, 129, 478. Epub 2013 Mar 25.

[52] Bakkum-Gamez J.N., Mariani A., Dowdy S.C., Weaver A.L., Mc-Gree M.E., Martin J.R., et al.: “Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy”. Gynecol. Oncol., 2014, 132, 578. Epub 2014 Jan 14.

[53] Creutzberg C.L.: “Adjuvant chemotherapy for endometrial cancer: unproven”. Int. J. Gynecol. Cancer, 2010, 20, 1105.

[54] Gilks C.B., Oliva E., Soslow R.A.: “Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma”. Am. J. Surg. Pathol., 2013, 37, 874.

[55] Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., et al.: “Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma”. Nature, 2013, 497, 67. Erratum in: Nature, 2013, 500, 242.

[56] Maggi R., Lissoni A., Spina F., Melpignano M., Zola P., Favalli G., et al.: “Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial”. Br. J. Cancer, 2006, 95, 266. Epub 2006 Jul 25.

[57] Shah P.H., Kudrimoti M., Feddock J., Randall M.: “Adjuvant treatment for stage IIIC endometrial cancer: options and controversies”. Gynecol. Oncol., 2011, 122, 675. Epub 2011 Jun 12.

[58] Onda T., Yoshikawa H., Mizutani K., Mishima M., Yokota H., Nagano H., et al.: ‘Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy”. Br. J. Cancer, 1997, 75, 1836.